According to data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.

Source: https://www.americanbankingnews.com/2023/01/09/3600-shares-in-gilead-sciences-inc-nasdaqgild-purchased-by-alta-advisers-ltd.html

Archford Capital Strategies LLC’s holdings in Gilead Sciences were worth $683,000 at the end of the most recent quarter.

Source: https://www.americanbankingnews.com/2023/06/29/archford-capital-strategies-llc-acquires-145-shares-of-gilead-sciences-inc-nasdaqgild.html

Bank Julius Baer & Co. Ltd Zurich’s holdings in Gilead Sciences were worth $31,530,000 as of its most recent SEC filing.

Source: https://www.americanbankingnews.com/2023/04/02/bank-julius-baer-co-ltd-zurich-has-31-53-million-stock-holdings-in-gilead-sciences-inc-nasdaqgild.html

Beacon Investment Advisory Services Inc. cut its holdings in Gilead Sciences, Inc. () by 0.5% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission.

Source: https://www.etfdailynews.com/2023/10/03/beacon-investment-advisory-services-inc-has-5-70-million-holdings-in-gilead-sciences-inc-nasdaqgild/

Concord Wealth Partners acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $33,000.

Source: https://www.etfdailynews.com/2023/06/24/massmutual-trust-co-fsb-adv-boosts-stake-in-gilead-sciences-inc-nasdaqgild/

Concord Wealth Partners acquired a new stake in Gilead Sciences in the fourth quarter worth $33,000.

Source: https://www.etfdailynews.com/2023/06/18/st-germain-d-j-co-inc-has-29000-position-in-gilead-sciences-inc-nasdaqgild/

Finally, Cowen lifted their price objective on Gilead Sciences from $90.00 to $95.00 in a research report on Friday, February 10th.

Source: https://www.etfdailynews.com/2023/04/01/meag-munich-ergo-kapitalanlagegesellschaft-mbh-buys-18554-shares-of-gilead-sciences-inc-nasdaqgild/

Finally, Ergoteles LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $2,304,000.

Source: https://www.dailypolitical.com/2023/01/23/gilead-sciences-inc-nasdaqgild-sees-significant-increase-in-short-interest.html

Finally, JFS Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 68.1% during the third quarter.

Source: https://www.americanbankingnews.com/2023/04/08/2908-shares-in-gilead-sciences-inc-nasdaqgild-bought-by-girard-partners-ltd.html

Finally, Oppenheimer increased their price objective on Gilead Sciences from $95.00 to $105.00 in a report on Thursday, December 1st.

Source: https://www.americanbankingnews.com/2023/02/04/gilead-sciences-nasdaqgild-releases-fy23-earnings-guidance.html

Finally, started coverage on shares of Gilead Sciences in a research note on Thursday, March 16th.

Source: https://www.americanbankingnews.com/2023/05/14/eversource-wealth-advisors-llc-sells-586-shares-of-gilead-sciences-inc-nasdaqgild.html

Gilead Sciences has a 52 week low of $57.17 and a 52 week high of $89.74.

Source: https://www.americanbankingnews.com/2023/02/04/gilead-sciences-nasdaqgild-releases-fy23-earnings-guidance.html

In my opinion, Gilead Sciences should be able to grow at least in the mid-single digits in the years to come.

Source: https://seekingalpha.com/article/4571511-gilead-sciences-stock-potential-to-continue-upward-trend?source=feed_all_articles

In other Gilead Sciences news, CFO sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th.

Source: https://www.americanbankingnews.com/2023/12/14/gilead-sciences-inc-nasdaqgild-shares-purchased-by-vicus-capital.html

Morgan Stanley grew its stake in Gilead Sciences by 11.5% during the 4th quarter.

Source: https://www.dailypolitical.com/2023/10/22/gilead-sciences-inc-nasdaqgild-shares-sold-by-lpl-financial-llc.html

Morgan Stanley lifted their price target on shares of Gilead Sciences from $81.00 to $85.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 12th.

Source: https://www.etfdailynews.com/2023/07/21/cantor-fitzgerald-cuts-gilead-sciences-nasdaqgild-price-target-to-80-00/

Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC Therapeutics, and Organogenesis are the leading players in the cell and gene therapy market.

Source: https://www.prnewswire.com/news-releases/germany-cell-and-gene-therapy-market---focused-insights-2023-2028-sector-to-reach-3-44-billion-by-2028-at-a-40-cagr-301784069.html

On average, analysts predict that Gilead Sciences, Inc. will post 6.83 earnings per share for the current year.

Source: https://www.americanbankingnews.com/2023/05/02/829-shares-in-gilead-sciences-inc-nasdaqgild-bought-by-hollencrest-capital-management.html

Wells Fargo & Company raised their price objective on Gilead Sciences from $75.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, January 3rd.

Source: https://www.etfdailynews.com/2023/04/01/meag-munich-ergo-kapitalanlagegesellschaft-mbh-buys-18554-shares-of-gilead-sciences-inc-nasdaqgild/

Within the large Pharmaceutical sector, stock prices were generally buoyant, with the "Big 8" US Pharmas - by order of market cap Johnson & Johnson (), Bristol Myers Squibb (), and Gilead Sciences (NASDAQ:) - realizing average share price gains of >15%.

Source: https://seekingalpha.com/article/4569436-eli-lilly-bears-making-huge-mistake?source=feed_all_articles